Leidos wins $545M biomedical research contract

Reston-based Fortune 500 government contractor Leidos Holdings Inc. won a potential $545 million contract to support biomedical research for the National Institute of Allergy and Infectious Diseases (NIAID), the company announced Wednesday.

Under the seven-year, indefinite delivery, indefinite quantity contract, Leidos will provide services including chemistry manufacturing and control, non-clinical research, analytics, computational biology, biostatistical services and other duties for the institute, which is led by Dr. Anthony Fauci, the nation’s leading expert on contagious diseases.

“Leidos is proud to support NIAID and provide world-class innovations to treat and prevent infectious, immunologic and allergic diseases,” Liz Porter, Leidos Health Group president, said in a statement. “For more than two decades, Leidos has supported the U.S. biomedical research community. We are pleased to continue this journey and provide robust biomedical research to reinforce NIAID and its important mission.”

The NIAID, National Institutes of Health, and the U.S. Department of Health and Human Services will fund the project in whole or in part.

Leidos provides technology, engineering and science services to defense, intelligence, civil and health markets. The company employs 43,000 people and reported $13.74 billion in 2021 revenue.